Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
Phase 2
Active, not recruiting
NCT03725761
| Condition | Prostate Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | University of Wisconsin, Madison |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 31 participants |
|---|
| Interventions | Sacituzumab Govitecan |
|---|
| Start date | Oct 24, 2018 |
|---|
| Completion date | Apr 18, 2024 |
|---|
| Results posted | Apr 24, 2025 |
|---|
Summary
This study will investigate the safety and efficacy of Sacituzumab Govitecan in patients with metastatic castration-resistant prostate cancer progressing on second generation androgen receptor (AR) directed therapy (e.g., enzalutamide, darolutamide, apalutamide and/or abiraterone).
PSA Response Rate
up to 9 weeks · percent
| Sacituzumab Govitecan Treatment | 6 percent |
|---|
6-Month Progression Free Survival Rate
6 months · percent
| Sacituzumab Govitecan Treatment | 52 percent |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.